Pyrrolotriazine kinase inhibitors

A compound of formula (I):

• 44
• or an enantiomer, diastereomer, or pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein
• Z is selected from O, S, N, OH, or Cl, with the provisos that when Z is O or S, R41 is absent and when Z is OH or Cl, both R and R42 are absent and when Z is N, then R41 is H;
• X and Y are independently selected from 0, OCO, S, SO, SO2, CO, CO2, NR10, NR11CO, NR12 CONR13, NR14CO2, NR15SO2, NR16SO2NR17, SO2NR18, CONR19, halogen, nitro, cyano, or X or Y are absent;
• R1 is hydrogen, CH3, OH, OCH3, SH, SCH3, OCOR21, SOR22, SO2R23, SO2NR24R25, CO2R26, CONR27R28, NH2, NR29SO2NR30R31, NR32SO2R33, NR34COR35, NR36CO2R37, NR38CONR39R40, halogen, nitro, or cyano;
• R2 and R3 are independently hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, aralkyl, substituted aralkyl, heterocycloalkyl or substituted heterocycloalkyl, or when X is halo, nitro or cyano R2 is absent or when Y is halo, nitro or cyano R3 is absent;
• R6 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, substituted heterocyclo, NR7R8, OR9 or halogen;
• R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R21, R24, R25, R26, R27, R28, R29, R30, R31, R32, R34, R35, R36, R38, R39 and R40 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, or substituted heterocyclo;
• R22, R23, R33 and R37 are independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heterocyclo, or substituted heterocyclo;
• and
• 45
• wherein
• each R43 is independently selected from fluorine or methyl;
• n is 0, 1 or 2;
• and
• R44 is methyl, ethyl or cyclopropylmethyl;
• with the further provisos that:
• a. R2 may not be hydrogen if X is SO, SO2, NR13CO2, or NR4SO2, and
• b. R3 may not be hydrogen if Y is SO, SO2, NR13CO2, or NR14SO2.